#United States #San Diego #Cortechs.ai #NeuroQuant #Siemens Healthineers

Cortechs.ai Teams Up with Siemens Healthineers

In a groundbreaking move poised to revolutionize neurology, Cortechs.ai, a leading player in AI-driven neuroimaging, has formed a strategic alliance with Siemens Healthineers. This partnership aims to broaden global access to NeuroQuant® technologies, a system designed to significantly improve brain imaging diagnostics and patient care.

A New Era of Neurological Diagnostics

The collaboration will enhance the integration of Cortechs.ai's FDA-approved NeuroQuant® Lesion Surveillance into Siemens Healthineers' prestigious Digital Marketplace. This is a significant leap toward addressing the needs of the neurology sector, particularly in the domain of complex dementia care pathways. Both companies emphasize the shared goal of optimizing clinical workflows and enhancing diagnostic accuracy through advanced technology.

One of the standout features of the NeuroQuant® Lesion Surveillance module is its automated segmentation capability, enabling clinicians to obtain volumetric quantification of brain lesions. This technology not only allows for real-time monitoring of lesion size and changes over time but also plays a critical role in the early detection of ARIA (Amyloid Related Imaging Abnormalities) in Alzheimer's patients receiving anti-amyloid therapies. Such developments are crucial as they pave the way for more personalized treatment plans and better patient outcomes.

Quotes from Industry Leaders

Kyle Frye, the CEO of Cortechs.ai, expressed enthusiasm regarding this partnership, calling it a pivotal step in expanding global access to advanced neuroimaging solutions. He noted, "By combining our innovative AI technologies with Siemens Healthineers' unmatched reach and imaging expertise, we're empowering clinicians with quicker and more precise insights, enabling informed decisions in Alzheimer’s and ARIA care."

Adding to this sentiment, Andreas Schneck, head of Magnetic Resonance at Siemens Healthineers, described the collaboration as a testament to their commitment to advancing healthcare. “We are excited to welcome Cortechs.ai's solutions into our Digital Marketplace. This collaboration reflects our dedication to providing clinicians with cutting-edge, interoperable tools that enhance diagnostic confidence and simplify workflows,” Schneck remarked.

Improved Clinical Workflows

The seamless integration of NeuroQuant® Lesion Surveillance into the Siemens Healthineers imaging ecosystem promises to streamline operations for radiologists and neurologists alike. Clinicians will be able to access quantitative data for treatment monitoring directly within their existing workflows, making it easier to track and assess neurological conditions over time.

This initiative underscores the urgency of addressing neurological disorders, particularly as they become increasingly prevalent in aging populations worldwide. The shift toward quantitative brain imaging through AI technology can facilitate earlier diagnoses, thereby offering more effective treatment options and improving the quality of life for patients.

About Cortechs.ai

Cortechs.ai stands at the forefront of AI applications in radiology, using state-of-the-art technologies to redefine disease screening and early detection. Their innovative software solutions are not only vital in assessing neurodegenerative diseases but also assist in significant cancer detection. With numerous FDA-clearances to their name, Cortechs.ai's products provide crucial insights for the diagnosis and follow-up of various conditions, including but not limited to Alzheimer’s, epilepsy, and multiple sclerosis.

For more insightful information about Cortechs.ai, visit www.cortechs.ai and stay updated through their social media channels.

Final Thoughts

The partnership between Cortechs.ai and Siemens Healthineers marks an exciting development in the healthcare landscape, particularly in the realm of brain health. As both companies seek to enhance access to vital neuroimaging technologies globally, the future looks promising for neurological diagnostics and patient care.